SPRO vs. MGNX, OGI, INBX, MDWD, ARTV, PRQR, NLTX, PROC, ZNTL, and HURA
Should you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include MacroGenics (MGNX), Organigram (OGI), Inhibrx (INBX), MediWound (MDWD), Artiva Biotherapeutics (ARTV), ProQR Therapeutics (PRQR), Neoleukin Therapeutics (NLTX), Procaps Group (PROC), Zentalis Pharmaceuticals (ZNTL), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry.
Spero Therapeutics vs.
MacroGenics (NASDAQ:MGNX) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.
Spero Therapeutics has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Spero Therapeutics had 4 more articles in the media than MacroGenics. MarketBeat recorded 7 mentions for Spero Therapeutics and 3 mentions for MacroGenics. MacroGenics' average media sentiment score of 1.32 beat Spero Therapeutics' score of 0.59 indicating that MacroGenics is being referred to more favorably in the media.
MacroGenics has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
MacroGenics received 218 more outperform votes than Spero Therapeutics when rated by MarketBeat users. However, 69.57% of users gave Spero Therapeutics an outperform vote while only 62.28% of users gave MacroGenics an outperform vote.
MacroGenics presently has a consensus target price of $7.63, indicating a potential upside of 146.76%. Spero Therapeutics has a consensus target price of $5.00, indicating a potential upside of 455.56%. Given Spero Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Spero Therapeutics is more favorable than MacroGenics.
96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 11.3% of MacroGenics shares are owned by insiders. Comparatively, 4.5% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Spero Therapeutics has a net margin of 3.30% compared to MacroGenics' net margin of -69.07%. Spero Therapeutics' return on equity of 4.03% beat MacroGenics' return on equity.
Summary
Spero Therapeutics beats MacroGenics on 10 of the 18 factors compared between the two stocks.
Get Spero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spero Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SPRO) was last updated on 1/15/2025 by MarketBeat.com Staff
